Literature DB >> 21280185

Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Ma Somsouk1, Rachel Kornfield, Eric Vittinghoff, John M Inadomi, Scott W Biggins.   

Abstract

Donor livers are offered to patients with the highest risk of death. How ascites could inform risk models to reduce liver transplant wait-list mortality is unclear. All adult candidates for primary liver transplantation for cirrhosis without exception points who were registered with the Organ Procurement and Transplantation Network from 2005 to 2007 composed our study cohort. Using Cox models and advanced discriminative metrics and paying attention to geographic disparities, we evaluated the additional risk discrimination of moderate ascites over that of the Model for End-Stage Liver Disease (MELD) or the Model for End-Stage Liver Disease plus serum sodium (MELD-Na) alone for the prediction of 90-day wait-list mortality. Additional analyses examined lower mortality risk candidates and those listed in high-demand, low-supply United Network for Organ Sharing regions in which accounting for ascites may most significantly affect wait-list mortality. Between 2005 and 2007, 18,124 subjects were listed for liver transplantation. Mortality was higher in patients with moderate ascites (15.4% versus 6.0%, P < 0.0001), and this risk persisted despite adjustments for MELD (hazard ratio = 1.58, 95% confidence interval = 1.42-1.76) and MELD-Na (hazard ratio = 1.42, 95% confidence interval = 1.28-1.58). The effect of moderate ascites was more prominent with a MELD score <21 (equal to 4.7 MELD units) or with a MELD-Na score <21 (equal to 3.5 MELD-Na units). Wait-list mortality was higher in patients with moderate ascites who were listed in high-demand, limited-supply regions (25.8% versus 17.5% at 1 year, P < 0.01). With the addition of moderate ascites, there was improvement in the overall risk model, particularly with a MELD score <21, as measured by the C index and integrated discrimination improvement. Moderate ascites informed risk prediction, particularly with a MELD score <21 and in high-demand, limited-supply regions. Under the MELD system, the presence of moderate ascites should prompt clinicians to consider strategies to expand access to transplantation, such as the use of extended donor liver grafts.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21280185      PMCID: PMC3058247          DOI: 10.1002/lt.22218

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  23 in total

1.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Authors:  Douglas M Heuman; Souheil G Abou-Assi; Adil Habib; Leslie M Williams; R Todd Stravitz; Arun J Sanyal; Robert A Fisher; Anastasios A Mihas
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

2.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites.

Authors:  J Llach; P Ginès; V Arroyo; A Rimola; L Titó; S Badalamenti; W Jiménez; J Gaya; F Rivera; J Rodés
Journal:  Gastroenterology       Date:  1988-02       Impact factor: 22.682

3.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

Review 4.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

5.  Survival and prognostic indicators in compensated and decompensated cirrhosis.

Authors:  G D'Amico; A Morabito; L Pagliaro; E Marubini
Journal:  Dig Dis Sci       Date:  1986-05       Impact factor: 3.199

6.  A prognostic model for predicting survival in cirrhosis with ascites.

Authors:  G Fernández-Esparrach; A Sánchez-Fueyo; P Ginès; J Uriz; L Quintó; P J Ventura; A Cárdenas; M Guevara; P Sort; W Jiménez; R Bataller; V Arroyo; J Rodés
Journal:  J Hepatol       Date:  2001-01       Impact factor: 25.083

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

8.  Circulating levels of endothelin in cirrhosis.

Authors:  M Asbert; A Ginès; P Ginès; W Jiménez; J Clària; J Saló; V Arroyo; F Rivera; J Rodés
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

9.  Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease.

Authors:  M Somsouk; J Guy; S W Biggins; E Vittinghoff; M A Kohn; J M Inadomi
Journal:  Aliment Pharmacol Ther       Date:  2009-07-13       Impact factor: 8.171

10.  Model for end-stage liver disease (MELD) and allocation of donor livers.

Authors:  Russell Wiesner; Erick Edwards; Richard Freeman; Ann Harper; Ray Kim; Patrick Kamath; Walter Kremers; John Lake; Todd Howard; Robert M Merion; Robert A Wolfe; Ruud Krom
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

View more
  29 in total

Review 1.  Living donor liver transplantation: eliminating the wait for death in end-stage liver disease?

Authors:  Robert A Fisher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-15       Impact factor: 46.802

2.  Impact of preoperative uncontrollable hepatic hydrothorax and massive ascites in adult liver transplantation.

Authors:  Kosuke Endo; Taku Iida; Shintaro Yagi; Atsushi Yoshizawa; Yasuhiro Fujimoto; Kohei Ogawa; Yasuhiro Ogura; Akira Mori; Toshimi Kaido; Shinji Uemoto
Journal:  Surg Today       Date:  2014-02-08       Impact factor: 2.549

3.  Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.

Authors:  David S Goldberg; Karen Krok; Sachin Batra; James F Trotter; Steven M Kawut; Michael B Fallon
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

4.  Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis.

Authors:  Avash Kalra; Joel P Wedd; Kiran M Bambha; Jane Gralla; Lucy Golden-Mason; Christine Collins; Hugo R Rosen; Scott W Biggins
Journal:  Liver Transpl       Date:  2017-02       Impact factor: 5.799

5.  Orthotopic liver transplantation for giant liver haemangioma: A case report.

Authors:  Undine G Lange; Julian N Bucher; Markus B Schoenberg; Christian Benzing; Moritz Schmelzle; Tanja Gradistanac; Steffen Strocka; Hans-Michael Hau; Michael Bartels
Journal:  World J Transplant       Date:  2015-12-24

Review 6.  Recent advances in our understanding of hepatorenal syndrome.

Authors:  Florence Wong
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-22       Impact factor: 46.802

7.  Model for End-Stage Liver Disease Underestimates Morbidity and Mortality in Patients with Ascites Undergoing Colectomy.

Authors:  Matthew M Fleming; Fangfang Liu; Yawei Zhang; Kevin Y Pei
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

8.  Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.

Authors:  Allison J Kwong; Jennifer C Lai; Jennifer L Dodge; John P Roberts
Journal:  Liver Transpl       Date:  2015-11       Impact factor: 5.799

9.  Defining long-term outcomes with living donor liver transplantation in North America.

Authors:  Kim M Olthoff; Abigail R Smith; Michael Abecassis; Talia Baker; Jean C Emond; Carl L Berg; Charlotte A Beil; James R Burton; Robert A Fisher; Chris E Freise; Brenda W Gillespie; David R Grant; Abhinav Humar; Igal Kam; Robert M Merion; Elizabeth A Pomfret; Benjamin Samstein; Abraham Shaked
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

Review 10.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.